268.80

0.57% 1.52

Praxis Precision Medicines Inc (PRAX)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$267.28

Offen:

$263.98

24-Stunden-Volumen:

402.80K

Relative Volume:

0.41

Marktkapitalisierung:

$6.72B

Einnahmen:

$1.77M

Nettoeinkommen (Verlust:

$-123.74M

KGV:

-29.31

EPS:

-9.17

Netto-Cashflow:

$-95.21M

1W Leistung:

+8.39%

1M Leistung:

+46.40%

6M Leistung:

+496.94%

1J Leistung:

+278.59%

1-Tages-Spanne:

$263.84

$274.35

1-Wochen-Bereich:

$251.00

$278.44

52-Wochen-Spanne:

$26.70

$278.44

Praxis Precision Medicines Inc Stock (PRAX) Company Profile

Firmenname

Praxis Precision Medicines Inc

Sektor

Healthcare (1123)

Branche

Biotechnology (627)

Telefon

617-300-8460

Adresse

99 HIGH STREET, 30TH FLOOR, BOSTON

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-11-06

Neueste SEC-Einreichungen

PRAX's Discussions on Twitter

Vergleichen Sie PRAX mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
PRAX Praxis Precision Medicines Inc	268.80	6.68B	1.77M	-123.74M	-95.21M	-9.17
VRTX Vertex Pharmaceuticals Inc	452.04	113.14B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	741.29	78.49B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	877.94	54.76B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	397.55	54.51B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	197.01	41.64B	447.02M	-1.18B	-906.14M	-6.1812

Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-11-19	Eingeleitet	BTIG Research	Buy
2025-06-02	Fortgesetzt	Oppenheimer	Outperform
2025-05-07	Eingeleitet	Chardan Capital Markets	Buy
2025-03-03	Bestätigt	H.C. Wainwright	Buy
2025-02-11	Eingeleitet	Deutsche Bank	Buy
2024-08-05	Eingeleitet	Oppenheimer	Outperform
2024-06-24	Eingeleitet	Needham	Buy
2024-06-18	Eingeleitet	Guggenheim	Buy
2024-05-01	Eingeleitet	Robert W. Baird	Outperform
2023-09-19	Eingeleitet	Truist	Buy
2022-06-06	Herabstufung	Wedbush	Outperform → Neutral
2021-12-16	Eingeleitet	H.C. Wainwright	Buy
2021-08-26	Eingeleitet	BofA Securities	Buy
2021-04-26	Eingeleitet	William Blair	Outperform
2020-11-11	Eingeleitet	Wedbush	Outperform
2020-11-10	Eingeleitet	Cowen	Outperform
2020-11-10	Eingeleitet	Evercore ISI	Outperform
2020-11-10	Eingeleitet	Piper Sandler	Overweight

Alle ansehen

Praxis Precision Medicines Inc Aktie (PRAX) Neueste Nachrichten

Dec 13, 2025

(PRAX) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com

Dec 13, 2025

Dec 12, 2025

Praxis Precision Medicines Plans New Drug Application - The Globe and Mail

Dec 12, 2025

Praxis Precision to file an NDA for relutrigine in encephalopathies in 2026 - Yahoo Finance

Dec 12, 2025

Deutsche Bank Raises Price Target on Praxis Precision Medicines to $313 From $303, Keeps Buy Rating - marketscreener.com

Dec 12, 2025

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Reduces Stock Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat

Dec 12, 2025

Praxis tees up another approval filing; Geron turns to layoffs - Yahoo Finance

Dec 12, 2025

Dec 11, 2025

Praxis Precision Medicines updates clinical trial design and regulatory plans - Investing.com

Dec 11, 2025

Praxis, FDA agree on pivotal trial changes for encephalopathy asset elsunersen - MSN

Dec 11, 2025

Praxis Precision Medicines Confirms FDA Filing Path for New Drug Application of Relutrigine in Early 2026 - Quiver Quantitative

Dec 11, 2025

TD Cowen lifts Praxis Precision Medicines Inc. (PRAX) price target amid NDA for essential tremor treatment - MSN

Dec 11, 2025

Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026 - Yahoo Finance

Dec 11, 2025

TD Cowen Lifts Praxis Precision Medicines Inc. (PRAX) Price Target amid NDA for Essential Tremor Treatment - Insider Monkey

Dec 11, 2025

HighVista Strategies LLC Buys 28,002 Shares of Praxis Precision Medicines, Inc. $PRAX - MarketBeat

Dec 11, 2025

Dec 10, 2025

Praxis a new buy at BTIG as biotech is a top pick for 2026 - MSN

Dec 10, 2025

Stempoint Capital LP Takes $1.36 Million Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat

Dec 10, 2025

Dec 09, 2025

PRAX Adjusts EMBRAVE3 Study Design After FDA Meeting - GuruFocus

Dec 09, 2025

Praxis Precision Medicines Announces FDA Approval for EMBRAVE3 Trial Design Change for Elsunersen in SCN2A Developmental and Epileptic Encephalopathy - Quiver Quantitative

Dec 09, 2025

Praxis Precision Medicines announces alignment with FDA - marketscreener.com

Dec 09, 2025

PRAX Stock Research: Jefferies Raises Price Target by 50% on Dec - GuruFocus

Dec 09, 2025

Praxis Precision (NASDAQ: PRAX) gets FDA nod for single-arm Elsunersen EMBRAVE3 trial - Stock Titan

Dec 09, 2025

Guggenheim Maintains Praxis Precision Medicines (PRAX) Buy Recommendation - Nasdaq

Dec 09, 2025

PRAX Stock Skyrockets 520% in 3 Months: Here's What You Need to Know - Eastern Progress

Dec 09, 2025

Praxis Precision Medicines (PRAX) Soars on FDA Momentum and 760-Dollar Target: December 9, 2025 Stock Deep Dive - ts2.tech

Dec 09, 2025

Vivo Capital LLC Takes Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat

Dec 09, 2025